Vir Biotechnology, Inc. (VIR) is a San Francisco-based clinical-stage biopharmaceutical company developing treatments for serious infectious diseases and cancer, most notably the hepatitis delta combination of elebsiran and tobevibart and a group of PRO-XTEN dual-masked T-cell engagers for solid tumors. On Friday, the stock dropped 15.84% to $10.20 shortly after the opening bell, a decline of $1.92 from the previous session's close of $12.12. The move lower is directly tied to the company's overnight pricing of a $150 million underwritten public offering at $10.00 per share, a level well below Thursday's close. Markets are reacting to dilution and to the discount the company accepted to raise capital.
Vir priced 15 million shares of common stock at $10.00 per share, for expected gross proceeds of $150 million before underwriting discounts, commissions, and expenses. Underwriters received a 30-day option to buy up to an additional 2.25 million shares on the same terms. The deal is scheduled to close November 16, subject to customary conditions, with Leerink Partners, Morgan Stanley, and Evercore ISI as joint bookrunning managers and Raymond James as co-manager.
The dilution math explains much of the selling. Against roughly 171.3 million shares outstanding, the new stock represents close to 9% of the existing share count, or about 10% if the option is fully exercised. The company's market capitalization sits near $1.75 billion at current prices, so a $150 million raise is a meaningful expansion of the equity base rather than a routine top-up.
Equity offerings are typically marketed at a discount to the last traded price, and this one was no exception: $10.00 versus Thursday's $12.12 close implies roughly a 17.5% markdown. That price quickly became the market's anchor. The stock opened at $10.47, slid to an intraday low of $10.15, and has since oscillated just above the offering level. Existing holders who did not participate see their stake diluted at a price below Thursday's value, which is why the initial reaction was concentrated in the first minutes of trading. The overhang usually compresses once the shares are delivered and the deal closes.
The raise did not arrive in a vacuum. Vir shares had roughly doubled year to date through Thursday and were up more than 120% over twelve months, leaving the stock vulnerable to any supply event. The rally was built on real news: Monday's session brought an 11.75% advance to $13.645 after the pivotal Phase 3 ECLIPSE 1 trial met its primary endpoint, with 79% of treated patients showing undetectable virus at week 48. The company also disclosed a licensing agreement with Gilead Sciences (GILD) potentially worth up to $1.9 billion for three oncology candidates. Proceeds from the offering are earmarked for commercial pre-launch activity in hepatitis delta and for the T-cell engager oncology platform, which extends a cash position of roughly $901 million that already funded operations into the second half of 2028. Dilution at a good news-driven valuation is a familiar financing pattern in clinical-stage biotech, and Friday's decline partly reflects holders locking in gains ahead of the new supply.
Volume was clearly elevated. Around 1.1 million shares traded in the first fifteen minutes of Friday's session, including more than 360,000 in the opening minute alone, against an average near 1.2 million shares for an entire day. The broader tape offered little support: the major biotech exchange-traded funds were down roughly 1.2% to 1.5% in the same window, while Gilead traded modestly lower. Vir's decline was therefore company-specific in scale, roughly ten times the sector's move, and consistent with a financing event rather than a sector-wide risk-off session.
Technically, the stock broke beneath its 20-day and 50-day simple moving averages, which sit near $11.47 and $11.18 respectively, in one gap. The session low of $10.15 has so far held above the $10.00 deal price, making that level the immediate pivot traders are watching.
The scale runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. This event scores 65 out of 100. The verified news is substantive: a $150 million raise equal to roughly a tenth of the share count, priced at a steep discount, is a material capital-structure event for a company of this size, though it is an ordinary financing tool for clinical-stage biotech rather than a fundamental shock. The price behavior was unusual. Friday's 15.84% decline was about 4.8 times the stock's average absolute daily move of 3.3% over the past sixty sessions, and no session in that window produced a move this large; the biggest prior swing was 11.75%. Strong but not transformative news combined with a rare, high-volume move produces a mid-range score.
The immediate checkpoint is November 16, when the offering is expected to settle and the final share count becomes known, including whether underwriters take the additional 2.25 million shares. Fourth-quarter and full-year 2026 results are expected in early 2027, and attention will focus on cash burn, the pace of pre-commercial spending, and any update on the timing of a regulatory submission for the hepatitis delta program, currently guided to mid-2027. The oncology story has its own milestones, including a planned pivotal program for VIR-5500 following its Fast Track designation.
Analyst coverage remains constructive, with consensus ratings uniformly bullish, though the discounted deal price may cap near-term upside until the new supply is absorbed. Key risks include continued dilution if additional capital is needed, execution and regulatory timing on the hepatitis delta filing, competitive pressure in viral hepatitis, and sensitivity to interest rates, which have weighed on long-dated development stories. Traders will also watch whether the stock stabilizes near $10.00 or continues to drift toward the lower end of its autumn range.
Tickeron maintains a curated Trending AI Robots page that highlights the trading bots performing strongest under current market conditions. The platform hosts hundreds of AI trading bots covering thousands of tickers, and this page narrows the field to the standout performers. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list rotates as conditions change. Investors seeking systematic, rules-based exposure may find the selection a useful starting point for further review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 38 of the 41 cases the stock fell afterwards. This puts the odds of success at 90%.
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
VIR moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 158 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases
Industry Biotechnology